Header Logo

Connection

JOHN KIRKWOOD to Survival Analysis

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Survival Analysis.
JOHN KIRKWOOD
Connection Strength
1.132
Survival Analysis
  1. NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018 11 15; 124(22):4332-4341.
    View in: PubMed
    Score: 0.071
  2. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 11 09; 377(19):1813-1823.
    View in: PubMed
    Score: 0.066
  3. Pediatric melanoma: analysis of an international registry. Cancer. 2013 Nov 15; 119(22):4012-9.
    View in: PubMed
    Score: 0.050
  4. Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med. 2012 Sep 05; 10:185.
    View in: PubMed
    Score: 0.046
  5. Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients. J Immunol Methods. 2012 Feb 28; 376(1-2):108-12.
    View in: PubMed
    Score: 0.044
  6. Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med. 2010 Nov 03; 8:108.
    View in: PubMed
    Score: 0.041
  7. Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. J Immunother. 2010 Apr; 33(3):316-25.
    View in: PubMed
    Score: 0.039
  8. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008 Jul 10; 26(20):3445-55.
    View in: PubMed
    Score: 0.035
  9. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 Feb 01; 26(4):527-34.
    View in: PubMed
    Score: 0.034
  10. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol. 2008 Jan; 5(1):2-3.
    View in: PubMed
    Score: 0.033
  11. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res. 2007 Mar 01; 13(5):1523-31.
    View in: PubMed
    Score: 0.032
  12. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006 Jul 01; 24(19):3164-71.
    View in: PubMed
    Score: 0.030
  13. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16; 354(7):709-18.
    View in: PubMed
    Score: 0.029
  14. Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma? Nat Clin Pract Oncol. 2005 May; 2(5):240-1.
    View in: PubMed
    Score: 0.028
  15. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004 Apr 15; 100(8):1692-8.
    View in: PubMed
    Score: 0.026
  16. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004 Mar 01; 10(5):1670-7.
    View in: PubMed
    Score: 0.026
  17. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol. 2002 Apr 15; 20(8):2053-7.
    View in: PubMed
    Score: 0.023
  18. Interferon alfa-2a for melanoma metastases. Lancet. 2002 Mar 16; 359(9310):978-9.
    View in: PubMed
    Score: 0.022
  19. An update on adjuvant interferon for melanoma. Cancer Control. 2002 Jan-Feb; 9(1):16-21.
    View in: PubMed
    Score: 0.022
  20. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 09 23; 385(13):1196-1206.
    View in: PubMed
    Score: 0.022
  21. Melanoma-specific expression of the tumor suppressor proteins p16 and PTEN is a favorable prognostic factor in established melanoma brain metastases. Melanoma Res. 2021 06 01; 31(3):264-267.
    View in: PubMed
    Score: 0.021
  22. CTLA-4 blockade and interferon-a induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLoS One. 2021; 16(1):e0245287.
    View in: PubMed
    Score: 0.021
  23. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000 Nov 15; 18(22):3782-93.
    View in: PubMed
    Score: 0.020
  24. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 09 17; 383(12):1139-1148.
    View in: PubMed
    Score: 0.020
  25. Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova). 2000 Jul-Sep; 10(3):230-9.
    View in: PubMed
    Score: 0.020
  26. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999 Sep; 17(9):2745-51.
    View in: PubMed
    Score: 0.019
  27. Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer. 2018 10 19; 6(1):108.
    View in: PubMed
    Score: 0.018
  28. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 07; 19(7):916-929.
    View in: PubMed
    Score: 0.017
  29. Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res. 2018 06; 28(3):211-221.
    View in: PubMed
    Score: 0.017
  30. Survival benefit in melanoma. J Clin Oncol. 1998 Jan; 16(1):388-9.
    View in: PubMed
    Score: 0.017
  31. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017 09 19; 5(1):74.
    View in: PubMed
    Score: 0.016
  32. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017 Dec 01; 35(34):3815-3822.
    View in: PubMed
    Score: 0.016
  33. Adjuvant interferon-a for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017 09; 82:171-183.
    View in: PubMed
    Score: 0.016
  34. Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma. Sci Rep. 2017 04 05; 7:45704.
    View in: PubMed
    Score: 0.016
  35. Comparison of prognostic indices in patients who undergo melanoma brain metastasis radiosurgery. J Neurosurg. 2018 01; 128(1):14-22.
    View in: PubMed
    Score: 0.016
  36. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan; 14(1):7-17.
    View in: PubMed
    Score: 0.015
  37. Does metastasectomy improve survival in skeletal melanoma? Melanoma Res. 2014 Aug; 24(4):354-9.
    View in: PubMed
    Score: 0.013
  38. Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int J Cancer. 2012 Aug 15; 131(4):874-84.
    View in: PubMed
    Score: 0.011
  39. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res. 2012 Feb 15; 18(4):1129-37.
    View in: PubMed
    Score: 0.011
  40. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30; 364(26):2507-16.
    View in: PubMed
    Score: 0.011
  41. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg. 2011 Mar; 114(3):769-79.
    View in: PubMed
    Score: 0.010
  42. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81.
    View in: PubMed
    Score: 0.009
  43. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007 Mar; 60(3):471-81; discussion 481-2.
    View in: PubMed
    Score: 0.008
  44. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006 Oct 10; 24(29):4738-45.
    View in: PubMed
    Score: 0.008
  45. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004 May-Jun; 54(3):131-49; quiz 182-4.
    View in: PubMed
    Score: 0.007
  46. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003 Jul 01; 98(1):100-9.
    View in: PubMed
    Score: 0.006
  47. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001 Aug 15; 19(16):3622-34.
    View in: PubMed
    Score: 0.005
  48. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001 Aug 15; 19(16):3635-48.
    View in: PubMed
    Score: 0.005
  49. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):581-9.
    View in: PubMed
    Score: 0.004
  50. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol. 1997 Nov; 15(11):3399-407.
    View in: PubMed
    Score: 0.004
  51. A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1997 Jun; 20(3):251-3.
    View in: PubMed
    Score: 0.004
  52. Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol. 1996 Nov; 19(6):433-42.
    View in: PubMed
    Score: 0.004
  53. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996 Oct; 14(10):2666-73.
    View in: PubMed
    Score: 0.004
  54. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1991 Oct; 9(10):1806-10.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.